Management of Type 1 Interatrial Septal Aneurysm
For asymptomatic patients with isolated type 1 interatrial septal aneurysm (ASA), observation with clinical follow-up is appropriate, but if there is a history of cryptogenic stroke or transient ischemic attack, particularly when associated with patent foramen ovale (PFO), antiplatelet therapy should be initiated and PFO closure should be strongly considered. 1
Risk Stratification and Initial Assessment
The clinical significance of ASA depends critically on associated abnormalities and symptom history:
Isolated ASA without embolic events: In approximately 32-36% of cases, ASA exists as an isolated structural defect without other cardiac abnormalities 2, 3. These patients generally require only observation, as children and asymptomatic adults with isolated ASA are not at significantly increased risk 3.
ASA with interatrial shunting: The majority (54-64%) of ASA patients have associated interatrial communications, most commonly PFO (found in 65-83% when assessed by transesophageal echocardiography with contrast and color flow mapping) 2, 4. This combination substantially increases embolic risk.
ASA with prior embolic events: Patients with ASA show a 44-52% frequency of previous clinical events compatible with cardiogenic embolism 2, 5. In patients with embolic events, 24-43% have no other identifiable cardiac source of embolism, making ASA the presumed culprit 2.
Diagnostic Workup
Transesophageal echocardiography (TEE) is essential for complete evaluation, as transthoracic echocardiography misses ASA in approximately 47% of cases 2:
- TEE with saline contrast and Valsalva maneuver is required to detect interatrial shunting, which is present in 83% of cases when properly assessed 4.
- TEE can identify high-risk features including multiple fenestrations, thrombus within the aneurysm (rare but present in 1-2% of cases), and membrane thickening ≥5 mm (found in 75% of patients with cerebrovascular events versus 27% without, p<0.05) 2, 4.
- TEE is recommended for detailed visualization of atrial septal anatomy when PFO closure is being considered 1.
Management Algorithm
For Patients WITHOUT Prior Embolic Events:
- Isolated ASA: Clinical observation with periodic follow-up 3.
- ASA with PFO but no symptoms: Consider antiplatelet therapy (typically aspirin), though evidence is limited for primary prevention in this population 1.
- Monitor for associated conditions: Valvular regurgitation (mitral in 39%, aortic in 16%) and supraventricular arrhythmias (16% of patients) are common concurrent pathologies 6.
For Patients WITH Cryptogenic Stroke or TIA:
The presence of ASA is recognized as a marker of increased embolic risk, particularly when combined with PFO 1, 2:
PFO closure plus antiplatelet therapy is recommended over antiplatelet therapy alone for secondary stroke prevention, based on 6 trials involving 3,560 patients 1.
Long-term anticoagulation should be considered in select cases, particularly when thrombus is visualized within the aneurysm or when paradoxical embolization is strongly suspected 4. However, PFO closure shows possible small reduction in stroke and decreased bleeding risk compared to anticoagulation alone 1.
Surgical excision of the aneurysmal septum with pericardial patch repair is reserved for rare cases with recurrent embolic events despite medical therapy or when thrombus is present within the aneurysm 5.
Important Clinical Considerations
Common pitfalls to avoid:
- Do not rely solely on transthoracic echocardiography, as it will miss nearly half of ASA cases 2.
- Estimating PFO size based on contrast amount in the left atrium is unreliable 1.
- The presence of ASA with PFO represents higher embolic risk than PFO alone, as ASA is "often associated with septal fenestrations and may be a marker of increased embolic risk" 1.
Special populations:
- Young adults born preterm with extremely low birthweight show significantly higher prevalence of ASA, particularly those with history of respiratory distress or patent ductus arteriosus at birth, and should undergo screening echocardiography 7.
Recurrent events: Patients with ASA and embolic events have a 67% rate of repeated cerebral events, underscoring the importance of aggressive secondary prevention 4.